Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | CYP2J2 | P51589 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.86 |
| ▸ | AR | P10275 | 2/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | APEX1 | P27695 | 1/20 | 0.86 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.86 |
| ▸ | IKBKB | O14920 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triamcinolone SCHEMBL14373318 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL1884154 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL1502196 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL601461 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL601462 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL24622562 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL4447 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL9863653 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL22962813 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL570639 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2527345-B1 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS INC (US) | 2015-12-16 | — | — | EP | claimed |
| EP-4271387-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF | Immunext, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-111417410-B | Glucocorticoid receptor agonists and immunoconjugates thereof | 艾伯维公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022150637-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | IMMUNEXT, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20220184116-A1 | MEDICAL AND NUTRITIONAL COMPOSITIONS AND METHODS OF USE | SULFILATEC INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-9938289-B2 | Therapeutic pyrazolyl thienopyridines | FBM THERAPEUTICS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9260450-B2 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2527345-B1 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS INC (US) | 2015-12-16 | — | — | EP | disclosed |
| US-9090625-B2 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2015-06-25 | — | — | US | disclosed |
| EP-2074128-B1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | MEDICIS PHARMACEUTICAL CORP (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8455512-B2 | Therapeutic pyrazolyl thienopyridines | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-06-04 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | NR3C1 970/4885HIF1A 2869/4885CYP3A4 481/4885 |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | NR3C1 970/4885HIF1A 2869/4885CYP3A4 481/4885 |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | NR3C1, NR3C2, C3AR1 | NR3C1 1/4885HIF1A 4459/4885CYP3A4 728/4885 |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | ACVR1, TGFBR1, ACVRL1 | NR3C1 495/4885HIF1A 1540/4885CYP3A4 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.